Pharma Mar : PharmaMar announces partnership with 8th National Race to End Women’s Cancer in support of “End Women´s Cancer Weekend” in Washington, D.C.

• According to the Foundation for Women´s Cancer, every 5 minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer
• PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer)

New York, November 4th, 2017. PharmaMar is pleased and honored to announce a new partnership supporting the 8th National Race to End Women's Cancer, the major awareness and fundraising event for the Fou nd ation f o r Wo men 's Can cer (FWC), which helps support research, education, and public awareness of gynecologic cancers. The Race features a 5K run and a 1-mile walk in downtown Washington, DC along historical Pennsylvania Avenue, NW, on Sunday morning, Nov. 5. Other activities held over the "En d Wo men 's Can cer Wee ken d " include a Survivor's Course offering patient and family resources, as well as other patient advocacy activities. Since 2009, the National Race to End Women's Cancer has brought together women and men of all ages from

across the United States to celebrate survivors, honor loved ones and raise awareness. This event is attended by patients, caregivers, families, physicians and others.

According to the Foundation for Women´s Cancer, every 5 minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer. More than 107,470 women with a gynecologic cancer will be diagnosed this year and about 31,600 will die from these cancers in 2017i.

PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer) and is currently awaiting data, expected early in 2018, for its pivotal Phase III trial, CORAIL, in platinum relapsed ovarian cancer with Zepsyre®. The Company is also planning on starting registrational trials, with the same molecule -Zepsyre®- in both BRCA2 mutated breast cancer and second line endometrial cancer during 2018.

their tremendous reach in the entire women's cancer community of patients, caregivers, physicians, advocates and others given our extensive clinical trials for Zepsyre in three of these cancers. I am honored to represent PharmaMar as a proud participant in this important event."

Karen Carlson, Executive Director of the Foundation for Women's Cancer, said "we're very excited and appreciative to have PharmaMar join the movement by sponsoring the 8th National Race to End Women's Cancer. We look forward to building upon our new partnership as we strive to increase public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment."

i American Cancer Society. Cancer Facts & Figures 2017. Atlanta; American Cancer Society; 2017.